UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

We think ResMed’s intangible brand has also enabled significant price premiums over less well ... device category and 30% higher in the CPAP category. This may reflect higher reimbursement ...

In recent trading, shares of ResMed Inc. (Symbol: RMD) have crossed above the average analyst 12-month target price of $253.00, changing hands for $254.70/share. When a stock reaches the target an ...